Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Garland

Showing results (741-750 of 803) with videos related to

Pageof 81
Sort By:
Emerging Infectious Diseases|September 21, 2016
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine GenotypesDavid Mesher, Kate Soldan, Matti Lehtinen, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
The American Surgeon|September 16, 2022
Low Prevalence but High Impact of COVID-19 Positive Status in Adult Trauma Patients: A Multi-institutional Analysis of 28 904 PatientsSamir M Fakhry, Jennifer L Morse, Jeneva M Garland, et al.
Journal of Trauma Nursing : the Official Journal of the Society of Trauma Nurses|February 20, 2026
Impact of Increasing Numbers of Trauma Activation Criteria on Outcomes and Resource Utilization: A Multicenter StudyNina Y Wilson, Harun Mazumder, Gina M Berg, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Science (New York, N.Y.)|September 18, 2010
Rainforest aerosols as biogenic nuclei of clouds and precipitation in the AmazonU Pöschl, S T Martin, B Sinha, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
The Journal of Infectious Diseases|March 1, 2026
Immunogenicity of HPV Vaccine in a High-Risk and Understudied Group: Female Sex WorkersTrang Van Nguyen, Le Anh Tuan, Chu Thi Ngoc Mai, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Pageof 81

Showing results (741-750 of 803) with videos related to

Sort By:
Pageof 81
Emerging Infectious Diseases|September 21, 2016
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine GenotypesDavid Mesher, Kate Soldan, Matti Lehtinen, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
The American Surgeon|September 16, 2022
Low Prevalence but High Impact of COVID-19 Positive Status in Adult Trauma Patients: A Multi-institutional Analysis of 28 904 PatientsSamir M Fakhry, Jennifer L Morse, Jeneva M Garland, et al.
Journal of Trauma Nursing : the Official Journal of the Society of Trauma Nurses|February 20, 2026
Impact of Increasing Numbers of Trauma Activation Criteria on Outcomes and Resource Utilization: A Multicenter StudyNina Y Wilson, Harun Mazumder, Gina M Berg, et al.
Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.
Science (New York, N.Y.)|September 18, 2010
Rainforest aerosols as biogenic nuclei of clouds and precipitation in the AmazonU Pöschl, S T Martin, B Sinha, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
The Journal of Infectious Diseases|March 1, 2026
Immunogenicity of HPV Vaccine in a High-Risk and Understudied Group: Female Sex WorkersTrang Van Nguyen, Le Anh Tuan, Chu Thi Ngoc Mai, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Pageof 81